Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects

Palliative and Supportive Care

Volumn 13, Issue 4, 2015, Pages 1079-1085

  Boettger, Soenke ^a   Jenewein, Josef ^a   Breitbart, William ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antipsychotics.; Aripiprazole; Delirium; Haloperidol; Olanzapine; Risperidone

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

AGED; COMPARATIVE STUDY; COMPLICATION; DELIRIUM; DEMENTIA; FEMALE; HUMAN; MALE; MIDDLE AGED;

AGED; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; BENZODIAZEPINES; DELIRIUM; DEMENTIA; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; RISPERIDONE;

EID: 84945547204     PISSN: 14789515     EISSN: 14789523     Source Type: Journal    
DOI: 10.1017/S1478951514001059     Document Type: Article

References (26)

1. American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders, 4th ed., Text Revision (DSM-IV-TR). Washington, DC, American Psychiatric Association (see esp. pp. 124-127).
2. Boettger, S., Friedlander, M., Breitbart, W., et al. (2011a). Aripiprazole and haloperidol in the treatment of delirium. The Australian and New Zealand Journal of Psychiatry, 45, 477-482.
3. Boettger, S., Passik, S. & Breitbart, W. (2011b). Treatment characteristics of delirium superimposed on dementia. International Psychogeriatrics, 23, 1671-1676.
4. Breitbart, W., Rosenfeld, B., Roth, A., et al. (1997). The Memorial Delirium Assessment Scale. Journal of Pain and Symptom Management, 13, 128-137.
5. Bucht, G., Gustafson, Y. & Sandberg, O. (1999). Epidemiology of delirium. Dementia and Geriatric Cognitive Disorders, 10, 315-318.
6. Camus, V., Burtin, B., Simeone, I., et al. (2000). Factor analysis supports the evidence of existing hyperactive and hypoactive subtypes of delirium. International Journal of Geriatric Psychiatry, 15, 313-316.
7. Elie, M., Cole, M.G., Primeau, F.J., et al. (1998). Delirium risk factors in elderly hospitalized patients. Journal of General Internal Medicine, 13, 204-212.
8. Grover, S., Kumar, V. & Chakrabarti, S. (2011). Comparative efficacy study of haloperidol, olanzapine, and risperidone in delirium. Journal of Psychosomatic Research, 71, 277-281.
9. Han, C.S.&Kim, Y.K. (2004). A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics, 45, 297-301.
10. Hu, H., Deng, W. & Yang, H. (2004). A prospective random control study comparison of olanzapine and haloperidol in senile delirium. Chongqing Medical Journal, 8, 1234-1237.
11. Jeste, D.V., Blazer, D., Casey, D., et al. (2008). ACNP white paper: Update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology, 33, 957-970.
12. Karnofsky, D.A. & Burchenal, J.H. (1949). The clinical evaluation of chemotherapeutic agents in cancer. In Evaluation of chemotherapeutic agents. C.M. Macleod (ed.), pp. 191-205. New York: Columbia University Press.
13. Kazmierski, J., Kowman, M., Banach, M., et al. (2008). Clinical utility and use of DSM-IVand ICD-10 criteria and the Memorial Delirium Assessment Scale in establishing a diagnosis of delirium after cardiac surgery. Psychosomatics, 49, 73-76.
14. Kim, J.Y., Jung, I.K., Han, C., et al. (2005). Antipsychotics and dopamine transporter gene polymorphisms in delirium patients. Psychiatry and Clinical Neurosciences, 59, 183-188.
15. Kim, S.W., Yoo, J.A., Lee, S.Y., et al. (2010). Risperidone versus olanzapine for the treatment of delirium. Human Psychopharmacology, 25, 298-302.
16. Lawlor, P.G., Nekolaichuk, C., Gagnon, B., et al. (2000). Clinical utility, factor analysis, and further validation of the Memorial Delirium Assessment Scale in patients with advanced cancer: Assessing delirium in advanced cancer. Cancer, 88, 2859-2867.
17. Lingjaerde, O., Ahlfors, U.G., Bech, P., et al. (1987). The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica, 334 (Suppl.), 1-100.
18. Lipowski, Z.J. (1989). Delirium in the elderly patient. The New England Journal of Medicine, 320, 578-582.
19. Liu, C.Y., Juang, Y.Y., Liang, H.Y., et al. (2004). Efficacy of risperidone in treating the hyperactive symptoms of delirium. International Clinical Psychopharmacology, 19, 165-168.
20. Lonergan, E., Britton, A.M., Luxenberg, J., et al. (2007). Antipsychotics for delirium. The Cochrane Database of Systematic Reviews, 18(2), CD005594.
21. Meagher, D.J., O'Hanlon, D., O'Mahony, E., et al. (2000). Relationship between symptoms and motoric subtype of delirium. The Journal of Neuropsychiatry and Clinical Neurosciences, 12, 51-56.
22. Rea, R.S., Battistone, S., Fong, J.J., et al. (2007). Atypical antipsychotics versus haloperidol for treatment of delirium in acutely ill patients. Pharmacotherapy, 27, 588-594.
23. Schneider, L.S., Dagerman, K.S. & Insel, P. (2005). Risk of death with atypical antipsychotic drug treatment for dementia: Metaanalysis of randomized placebo-controlled trials. The Journal of the American Medical Association, 19(294), 1934-1943.
24. Skrobik, Y.K., Bergeron, N., Dumont, M., et al. (2004). Olanzapine vs. haloperidol: Treating delirium in a critical care setting. Intensive Care Medicine, 30, 444-449.
25. Trzepacz, P.T., Breitbart, W., Franklin, J., et al. (1999). Practice guideline for the treatment of patients with delirium: American Psychiatric Association. The American Journal of Psychiatry, 156, 1-20.
26. Yoon, H.J., Park, K.M., Choi, W.J., et al. (2013). Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. BMC Psychiatry, 13, 240.